List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4252958/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overexpression of the Cytokine BAFF and Autoimmunity Risk. New England Journal of Medicine, 2017, 376, 1615-1626.	27.0	301
2	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Multiple Sclerosis Journal, 2006, 12, 814-823.	3.0	206
3	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	6.1	184
4	Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature Genetics, 2010, 42, 495-497.	21.4	164
5	Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. PLoS ONE, 2012, 7, e32487.	2.5	147
6	Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Human Molecular Genetics, 2001, 10, 2907-2916.	2.9	134
7	Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet, The, 2002, 359, 1461-1465.	13.7	112
8	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
9	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	1.8	99
10	Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
11	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
12	Association of Mycobacterium avium subsp. paratuberculosis with Multiple Sclerosis in Sardinian Patients. PLoS ONE, 2011, 6, e18482.	2.5	85
13	Familial effects on the clinical course of multiple sclerosis. Neurology, 2007, 68, 376-383.	1.1	77
14	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.1	74
15	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	3.0	72
16	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Annals of Neurology, 2006, 59, 634-639.	5.3	69
17	Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes and Immunity, 2009, 10, 15-17.	4.1	69
18	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.1	68

#	Article	IF	CITATIONS
19	¹ H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e185.	6.0	68
20	Epidemiology of multiple sclerosis in south-western Sardinia. Multiple Sclerosis Journal, 2011, 17, 1282-1289.	3.0	66
21	Age at onset in multiple sclerosis. Neurological Sciences, 2000, 21, S825-S829.	1.9	65
22	Alemtuzumab long-term immunologic effect. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e194.	6.0	65
23	The risk of Bipolar Disorders in Multiple Sclerosis. Journal of Affective Disorders, 2014, 155, 255-260.	4.1	61
24	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. Multiple Sclerosis and Related Disorders, 2016, 10, 187-191.	2.0	61
25	Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. Journal of the Neurological Sciences, 2015, 358, 339-344.	0.6	57
26	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9,	6.0	57
27	Epstein–Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2014, 270, 51-55.	2.3	56
28	Clinical activity after fingolimod cessation: disease reactivation or rebound?. European Journal of Neurology, 2018, 25, 1270-1275.	3.3	56
29	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	6.1	54
30	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	3.0	53
31	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	7.6	53
32	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 448-450.	1.9	53
33	Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score. Journal of the Neurological Sciences, 2014, 345, 159-163.	0.6	52
34	Assessing association of comorbidities with treatment choice and persistence in MS. Neurology, 2017, 89, 2222-2229.	1.1	50
35	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. BMC Neurology, 2013, 13, 177.	1.8	48
36	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48

#	Article	IF	CITATIONS
37	Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by <i>LMNA</i> gene mutations. Muscle and Nerve, 2010, 41, 458-463.	2.2	44
38	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. International Journal of Biochemistry and Cell Biology, 2017, 93, 148-155.	2.8	44
39	"Better explanations―in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.1	44
40	Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study. PLoS ONE, 2013, 8, e59711.	2.5	43
41	Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. Scientific Reports, 2016, 6, 22401.	3.3	42
42	Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. Frontiers in Immunology, 2021, 12, 781843.	4.8	42
43	The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Human Molecular Genetics, 2004, 13, 2919-2924.	2.9	41
44	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. Journal of Affective Disorders, 2014, 167, 192-197.	4.1	40
45	Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 2472-2477.	3.6	40
46	Top-down proteomic profiling of human saliva in multiple sclerosis patients. Journal of Proteomics, 2018, 187, 212-222.	2.4	40
47	Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 1200-1202.	3.0	39
48	Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. Gait and Posture, 2017, 58, 307-309.	1.4	39
49	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	4.4	39
50	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. PLoS ONE, 2012, 7, e41678.	2.5	38
51	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38
52	Cerebrospinal fluid findings in Devic?s neuromyelitis optica. Neurological Sciences, 2004, 25, s368-s370.	1.9	37
53	Human interferon regulatory factor 5 homologous epitopes of <i>Epstein-Barr</i> virus and <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> induce a specific humoral and cellular immune response in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 984-995.	3.0	37
54	HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 327-327.	1.9	36

#	Article	IF	CITATIONS
55	The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 607-616.	2.8	36
56	Determinants of therapy switch in multiple sclerosis treatment-naÃ ⁻ ve patients: A real-life study. Multiple Sclerosis Journal, 2019, 25, 1263-1272.	3.0	36
57	A novel Cx32 mutation causes X-linked Charcot-Marie-Tooth disease with brainstem involvement and brain magnetic resonance spectroscopy abnormalities. Neurological Sciences, 2006, 27, 18-23.	1.9	35
58	Moderate Exercise Improves Cognitive Function in Healthy Elderly People: Results of a Randomized Controlled Trial. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 75-80.	1.2	35
59	HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia. PLoS ONE, 2012, 7, e33972.	2.5	34
60	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
61	Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. Acta Myologica, 2013, 32, 7-17.	1.5	33
62	Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the lamininâ€Î±2â€chain gene: A chance association or a novel phenotype?. Muscle and Nerve, 2011, 44, 826-828.	2.2	32
63	Influence of treatments in multiple sclerosis disability: A cohort study. Multiple Sclerosis Journal, 2015, 21, 433-441.	3.0	32
64	Cladribine vs other drugs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	32
65	Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. Leukemia, 2006, 20, 2217-2218.	7.2	31
66	Are <i>Mycobacterium</i> avium subsp. <i>paratuberculosis</i> and Epstein–Barr virus triggers of multiple sclerosis in Sardinia?. Multiple Sclerosis Journal, 2012, 18, 1181-1184.	3.0	31
67	<i>Mycobacterium avium subsp. paratuberculosis</i> and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Multiple Sclerosis Journal, 2013, 19, 1437-1442.	3.0	31
68	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	1.8	31
69	Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. Journal of Neurology, 2019, 266, 1405-1411.	3.6	31
70	Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224.	1.9	30
71	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work, 2018, 60, 263-270.	1.1	30
72	Walking in multiple sclerosis improves with tDCS: a randomized, doubleâ€blind, shamâ€controlled study. Annals of Clinical and Translational Neurology, 2020, 7, 2310-2319.	3.7	30

#	Article	IF	CITATIONS
73	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111.	3.0	30
74	Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. Annals of Hematology, 2004, 83, 403-405.	1.8	29
75	Managing MS in a changing treatment landscape. Journal of Neurology, 2011, 258, 728-739.	3.6	29
76	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. Journal of Neuroimmunology, 2015, 280, 66-68.	2.3	29
77	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurology, 2018, 18, 67.	1.8	27
78	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	1.9	27
79	Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients. Molecular Immunology, 2014, 57, 138-140.	2.2	26
80	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. Multiple Sclerosis Sclerosis and Related Disorders, 2017, 15, 1-6.	2.0	26
81	Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study. PLoS ONE, 2020, 15, e0236090.	2.5	26
82	Active elderly and health—can moderate exercise improve health and wellbeing in older adults? Protocol for a randomized controlled trial. Trials, 2021, 22, 331.	1.6	26
83	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
84	EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. Journal of Neuroimmunology, 2013, 264, 120-122.	2.3	25
85	The burden of multiple sclerosis and patients' coping strategies. BMJ Supportive and Palliative Care, 2018, 8, 38-40.	1.6	25
86	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. PLoS ONE, 2013, 8, e59790.	2.5	25
87	Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation. Neurology, 2006, 66, 108-111.	1.1	24
88	Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel LMNA gene mutation. Neuromuscular Disorders, 2008, 18, 291-298.	0.6	24
89	Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. Journal of the Neurological Sciences, 2013, 335, 131-133.	0.6	24
90	Antigenic peptide molecular recognition by the DRB1–DQB1 haplotype modulates multiple sclerosis susceptibility. Molecular BioSystems, 2014, 10, 2043-2054.	2.9	24

#	Article	IF	CITATIONS
91	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	3.0	24
92	Cognition in multiple sclerosis: Between cognitive reserve and brain volume. Journal of the Neurological Sciences, 2018, 386, 19-22.	0.6	24
93	Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers. BMC Neurology, 2018, 18, 212.	1.8	24
94	Chromosome 7q21–22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. Journal of Neuroimmunology, 2002, 125, 141-148.	2.3	23
95	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 975-980.	3.0	23
96	A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. Journal of Neurology, 2018, 265, 1174-1183.	3.6	23
97	PML in a person with multiple sclerosis. Neurology, 2018, 90, 83-85.	1.1	23
98	The Relationships between Physical Activity, Self-Efficacy, and Quality of Life in People with Multiple Sclerosis. Behavioral Sciences (Basel, Switzerland), 2019, 9, 121.	2.1	23
99	Effectiveness and Limitations of Unsupervised Home-Based Balance Rehabilitation with Nintendo Wii in People with Multiple Sclerosis. BioMed Research International, 2015, 2015, 1-8.	1.9	22
100	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	2.4	22
101	Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. Journal of Infection in Developing Countries, 2013, 7, 203-207.	1.2	22
102	Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. Muscle and Nerve, 2013, 48, 161-170.	2.2	21
103	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	3.6	21
104	Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. Disability and Rehabilitation, 2018, 40, 144-151.	1.8	21
105	Gait and Functional Mobility in Multiple Sclerosis: Immediate Effects of Transcranial Direct Current Stimulation (tDCS) Paired With Aerobic Exercise. Frontiers in Neurology, 2020, 11, 310.	2.4	21
106	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological Sciences, 2013, 34, 1633-1637.	1.9	20
107	Induction and Escalation Therapies in Multiple Sclerosis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2015, 14, 26-34.	1.1	20
108	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study Multiple Sclerosis and Related Disorders, 2019, 27, 74-78.	2.0	20

#	Article	IF	CITATIONS
109	Cardiac and muscle imaging findings in a family with X-linked Emery–Dreifuss muscular dystrophy. Neuromuscular Disorders, 2012, 22, 152-158.	0.6	19
110	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurological Sciences, 2014, 35, 401-408.	1.9	19
111	Attitude towards physical activity in patients with multiple sclerosis: a cohort study. Neurological Sciences, 2015, 36, 889-893.	1.9	19
112	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.0	19
113	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 132.	7.2	18
114	Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Scientific Reports, 2016, 6, 29268.	3.3	18
115	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. Journal of Neurology, 2017, 264, 973-978.	3.6	18
116	Do gait patterns differ in men and women with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2017, 18, 202-208.	2.0	18
117	Texting while walking differently alters gait patterns in people with multiple sclerosis and healthy individuals. Multiple Sclerosis and Related Disorders, 2018, 19, 129-133.	2.0	18
118	The Use of Social Media and Digital Devices Among Italian Neurologists. Frontiers in Neurology, 2020, 11, 583.	2.4	18
119	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203.	1.9	17
120	Cardiac involvement in patients with lamin A/C gene mutations: A cohort observation. Muscle and Nerve, 2012, 46, 187-192.	2.2	17
121	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 961-963.	3.0	17
122	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Neurotherapeutics, 2019, 16, 797-807.	4.4	17
123	A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 120-123.	2.3	16
124	Evolution of the phenotype in a family with an <i>LMNA</i> gene mutation presenting with isolated cardiac involvement. Muscle and Nerve, 2010, 41, 85-91.	2.2	16
125	History of multiple sclerosis in 2 successive pregnancies. Neurology, 2016, 87, 1360-1367.	1.1	16
126	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study. Journal of Neurology, 2019, 266, 2440-2446.	3.6	16

#	Article	IF	CITATIONS
127	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. Journal of Neurology, 2018, 265, 1328-1333.	3.6	15
128	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1093-1099.	2.2	15
129	Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers. International Journal of Environmental Research and Public Health, 2020, 17, 8848.	2.6	15
130	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences, 2020, 41, 3185-3193.	1.9	15
131	An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. Drug Design, Development and Therapy, 2021, Volume 15, 1993-2004.	4.3	15
132	A realâ€world study of alemtuzumab in a cohort of Italian patients. European Journal of Neurology, 2022, 29, 257-266.	3.3	15
133	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. PLoS ONE, 2016, 11, e0163313.	2.5	15
134	ICAM-1 gene is not associated with multiple sclerosis in sardinian patients. Journal of Neurology, 2000, 247, 677-680.	3.6	14
135	Progressive multiple sclerosis and mood disorders. Neurological Sciences, 2015, 36, 1625-1631.	1.9	14
136	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case–control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	3.6	14
137	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. Journal of Neurology, 2019, 266, 707-716.	3.6	14
138	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	2.0	14
139	The effect of a telerehabilitation virtual reality intervention on functional upper limb activities in people with multiple sclerosis: a study protocol for the TEAMS pilot randomized controlled trial. Trials, 2020, 21, 713.	1.6	14
140	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle and Nerve, 2014, 49, 928-930.	2.2	13
141	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	5.0	13
142	â€~Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. Journal of Neurology, 2017, 264, 2201-2204.	3.6	13
143	Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 173-180.	2.8	13
144	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. Multiple Sclerosis Journal, 2021, 27, 1332-1340.	3.0	13

#	Article	IF	CITATIONS
145	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
146	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	2.3	12
147	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. Journal of Neurology, 2006, 253, 208-213.	3.6	12
148	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. Journal of the Neurological Sciences, 2015, 349, 249-250.	0.6	12
149	Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach. PLoS ONE, 2019, 14, e0226162.	2.5	12
150	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	3.3	12
151	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. Neurology and Therapy, 2022, 11, 39-49.	3.2	12
152	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2004, 251, 1085-8.	3.6	11
153	Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. Neurology, 2005, 65, 490-490.	1.1	11
154	Charcot–Marie–Tooth disease: genetic subtypes in the Sardinian population. Neurological Sciences, 2017, 38, 1019-1025.	1.9	11
155	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. Multiple Sclerosis Journal, 2019, 25, 23-30.	3.0	11
156	The impact of deep grey matter volume on cognition in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102351.	2.0	11
157	Kinematic Analysis of Lower Limb Joint Asymmetry During Gait in People with Multiple Sclerosis. Symmetry, 2021, 13, 598.	2.2	11
158	Efficacy and Safety of Quetiapine Treatment for Delusional Parasitosis. Clinical Neuropharmacology, 2008, 31, 310-312.	0.7	10
159	Aberrant splicing in the <i>LMNA</i> gene caused by a novel mutation on the polypyrimidine tract of intron 5. Muscle and Nerve, 2011, 43, 688-693.	2.2	10
160	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurological Sciences, 2012, 33, 863-867.	1.9	10
161	Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35–55, in multiple sclerosis patients. Journal of the Neurological Sciences, 2014, 347, 78-81.	0.6	10
162	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 759.	2.0	10

#	Article	IF	CITATIONS
163	The burden of multiple sclerosis variants in continental Italians and Sardinians. Multiple Sclerosis Journal, 2015, 21, 1385-1395.	3.0	10
164	Effects of Six Months Training on Physical Capacity and Metaboreflex Activity in Patients with Multiple Sclerosis. Frontiers in Physiology, 2016, 7, 531.	2.8	10
165	Long-term follow-up more than 10Âyears after HSCT: a monocentric experience. Journal of Neurology, 2018, 265, 410-416.	3.6	10
166	Adult brain volume in multiple sclerosis: The impact of paediatric onset. Multiple Sclerosis and Related Disorders, 2018, 21, 103-107.	2.0	10
167	Validation of the Arm Profile Score in assessing upper limb functional impairments in people with multiple sclerosis. Clinical Biomechanics, 2018, 51, 45-50.	1.2	10
168	Association between brain atrophy and cognitive motor interference in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 208-211.	2.0	10
169	What happens after fingolimod discontinuation? A multicentre real-life experience. Journal of Neurology, 2022, 269, 796-804.	3.6	10
170	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944.	3.6	10
171	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. Multiple Sclerosis and Related Disorders, 2018, 20, 104-108.	2.0	9
172	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. Multiple Sclerosis and Related Disorders, 2018, 22, 8-11.	2.0	9
173	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. Multiple Sclerosis and Related Disorders, 2018, 23, 83-87.	2.0	9
174	Timed Up and Go in men and women with Multiple Sclerosis: Effect of muscular strength. Journal of Bodywork and Movement Therapies, 2020, 24, 124-130.	1.2	9
175	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	4.4	9
176	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.6	9
177	Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study. Multiple Sclerosis and Related Disorders, 2022, 65, 104004.	2.0	9
178	Relationship between gait initiation and disability in individuals affected by multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 594-597.	2.0	8
179	Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-Î ² Therapy in Multiple Sclerosis Patients. Journal of Molecular Neuroscience, 2016, 60, 91-93.	2.3	8
180	Combining HLA-DRB1-DQB1 and Mycobacterium Avium Subspecies Paratubercolosis (MAP) antibodies in Sardinian multiple sclerosis patients: associated or independent risk factors?. BMC Neurology, 2016, 16, 148.	1.8	8

#	Article	IF	CITATIONS
181	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 2017, 313, 89-91.	2.3	8
182	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
183	The impact of secondary infections in COVID-19 critically ill patients. Journal of Infection, 2022, 84, e116-e117.	3.3	8
184	The contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs. Annals of Neurology, 2000, 47, 411-412.	5.3	7
185	Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon β1B. Journal of Neurology, 2005, 252, 1420-1422.	3.6	7
186	Juvenile Multiple Sclerosis Similar to Type I Diabetes Mellitus has a Seasonality of Month of Birth which Differs from that in the General Population. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 473-7.	0.9	7
187	Oxcarbazepine-Induced Leukopenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 502-503.	1.8	7
188	Prevalence of Huntington's disease in Southern Sardinia, Italy. Parkinsonism and Related Disorders, 2020, 80, 54-57.	2.2	7
189	What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?. Medicine (United States), 2021, 100, e24931.	1.0	7
190	Use of wrist-worn accelerometers to quantify bilateral upper limb activity and asymmetry under free-living conditions in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103081.	2.0	7
191	Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. Frontiers in Immunology, 2021, 12, 728677.	4.8	7
192	Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2002, 249, 1552-1555.	3.6	6
193	Variation of the Myelin Oligodendrocyte Clycoprotein gene is not primarily associated with multiple sclerosis in the Sardinian population. BMC Genetics, 2007, 8, 25.	2.7	6
194	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. Journal of the Neurological Sciences, 2015, 357, 229-234.	0.6	6
195	The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait. Multiple Sclerosis and Related Disorders, 2016, 10, 174-178.	2.0	6
196	Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. European Journal of Neurology, 2018, 25, 1063-1068.	3.3	6
197	Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis. Multiple Sclerosis International, 2019, 2019, 1-6.	0.8	6
198	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. PLoS ONE, 2019, 14, e0226615.	2.5	6

#	Article	IF	CITATIONS
199	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. Disability and Rehabilitation, 2020, 42, 737-742.	1.8	6
200	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102145.	2.0	6
201	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	1.9	6
202	IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients. Microorganisms, 2020, 8, 500.	3.6	6
203	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.3	6
204	Event-related potentials and deep grey matter atrophy in multiple sclerosis: Exploring the possible associations with cognition. Multiple Sclerosis and Related Disorders, 2021, 49, 102785.	2.0	6
205	Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil. Experimental Neurology, 2022, 347, 113906.	4.1	6
206	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	5.3	6
207	Inter-joint coordination during gait in people with multiple sclerosis: A focus on the effect of disability. Multiple Sclerosis and Related Disorders, 2022, 60, 103741.	2.0	6
208	Is multiple sclerosis severity a genetically influenced trait?. Neurological Sciences, 2000, 21, S843-S847.	1.9	5
209	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. Multiple Sclerosis and Related Disorders, 2016, 7, 65-67.	2.0	5
210	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. Multiple Sclerosis and Related Disorders, 2020, 46, 102564.	2.0	5
211	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 2022, 13, 818325.	4.8	5
212	The cohort of the multiple sclerosis center of Cagliari. Neurological Sciences, 2011, 31, 309-312.	1.9	4
213	Oral Agents in Multiple Sclerosis. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2015, 14, 15-25.	1.1	4
214	Mitoxantrone exposure in pregnancy: a new case report in a multiple sclerosis patient. Case Reports in Perinatal Medicine, 2016, 5, 125-126.	0.1	4
215	Assessing measurement invariance of MSQOL-54 across Italian and English versions. Quality of Life Research, 2020, 29, 783-791.	3.1	4
216	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	2.0	4

#	Article	IF	CITATIONS
217	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103909.	2.0	4
218	Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. Multiple Sclerosis Journal, 2009, 15, 1030-1036.	3.0	3
219	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 2013, 34, 197-203.	1.9	3
220	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. Multiple Sclerosis Journal, 2018, 24, 231-233.	3.0	3
221	Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. Neurological Sciences, 2018, 39, 389-390.	1.9	3
222	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	2.0	3
223	Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. Functional Neurology, 2006, 21, 145-9.	1.3	3
224	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
225	Cyclograms Reveal Alteration of Inter-Joint Coordination during Gait in People with Multiple Sclerosis Minimally Disabled. Biomechanics, 2022, 2, 331-341.	1.2	3
226	Cortical Pathology in RRMS: Taking a Cue from Four Sisters. Multiple Sclerosis International, 2012, 2012, 1-6.	0.8	2
227	Long-term benefits of induction therapy in NMO: a case report. Neurological Sciences, 2014, 35, 1831-1832.	1.9	2
228	Brain volume in early MS patients with and without IgG oligoclonal bands in CSF. Multiple Sclerosis and Related Disorders, 2018, 19, 55-58.	2.0	2
229	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. Multiple Sclerosis and Related Disorders, 2020, 45, 102394.	2.0	2
230	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. Health and Quality of Life Outcomes, 2021, 19, 224.	2.4	2
231	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. Frontiers in Neurology, 2021, 12, 679355.	2.4	2
232	A Novel Mutation in Lamin A/C Gene: Phenotype and Consequences on the Protein Structure and Flexibility. SRX Biology, 2010, 2010, 1-7.	0.0	2
233	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. Biomolecules, 2022, 12, 677.	4.0	2
234	Muscle <scp>MRI</scp> in female carriers of emerinopathy. European Journal of Neurology, 2013, 20, e127.	3.3	1

#	Article	IF	CITATIONS
235	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. Neurological Sciences, 2015, 36, 2213-2220.	1.9	1
236	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
237	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.6	1
238	Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I. Frontiers in Medicine, 2020, 7, 163.	2.6	1
239	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. Neurological Sciences, 2021, 42, 5177-5181.	1.9	1
240	Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers. Frontiers in Neurology, 2021, 12, 636463.	2.4	1
241	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110590.	1.0	1
242	Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1192-1192.	1.9	0
243	Informing MS patients on treatment options: a consensus on the process of consent taking. Neurological Sciences, 2020, 41, 2249-2253.	1.9	0
244	EDSS trajectories in multiple sclerosis patients from the Italian MS register. Journal of the Neurological Sciences, 2021, 429, 117824.	0.6	0
245	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. Journal of the Neurological Sciences, 2021, 429, 117749.	0.6	0
246	TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy. Current Medical Imaging, 2017, 14, 95-98.	0.8	0